Figure 1.
Activated platelet-targeting improves the clot lysis efficiency of SCE5-scuPA. (A and B) Collation of percent clot degradation curves of naive whole blood for 100 nM SCE5-scuPA (A) and nontargeted mut-scuPA control (B), respectively. (C) Fifty percent clot degradation time (T0.5). (D) Time until clot lysis initiation (At). (E) CLRmax achieved during clot lysis. (F) CLRmax calculated from 100 nM SCE5-scuPA and mut-scuPA on clots prepared with reconstituted whole blood mixtures with a platelet-concentration gradient (Clot 1 = 60% platelets [vol/vol]; Clot 7 = no platelets). All data presented as mean ± standard deviation. #P < .05, ##P < .01, ###P < .001 by 2-way analysis of variance with Šidák’s post hoc analysis. ∗P < .05, ∗∗∗P < .001 by a t test (unpaired, 2-tailed). n = 3.

Activated platelet-targeting improves the clot lysis efficiency of SCE5-scuPA. (A and B) Collation of percent clot degradation curves of naive whole blood for 100 nM SCE5-scuPA (A) and nontargeted mut-scuPA control (B), respectively. (C) Fifty percent clot degradation time (T0.5). (D) Time until clot lysis initiation (At). (E) CLRmax achieved during clot lysis. (F) CLRmax calculated from 100 nM SCE5-scuPA and mut-scuPA on clots prepared with reconstituted whole blood mixtures with a platelet-concentration gradient (Clot 1 = 60% platelets [vol/vol]; Clot 7 = no platelets). All data presented as mean ± standard deviation. #P < .05, ##P < .01, ###P < .001 by 2-way analysis of variance with Šidák’s post hoc analysis. ∗P < .05, ∗∗∗P < .001 by a t test (unpaired, 2-tailed). n = 3.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal